Autoimmunity in chronic lymphocytic leukemia

Current Treatment Options in Oncology

Volumn 2, Issue 3, 2001, Pages 253-257

  Ward, John H ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic Lymphocytic Leukemia; Fludarabine; Main Drug Interaction; Main Side Effect; Thrombotic Thrombocytopenic Purpura

Indexed keywords

ANTINEOPLASTIC AGENT; AUTOANTIBODY; AUTOANTIGEN; CORTICOSTEROID;

AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNITY; CHRONIC LYMPHATIC LEUKEMIA; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOLOGY; PHYSIOLOGY; PURE RED CELL ANEMIA; RADIOTHERAPY; REVIEW; SPLENECTOMY;

ADRENAL CORTEX HORMONES; ANEMIA, HEMOLYTIC, AUTOIMMUNE; ANTINEOPLASTIC AGENTS; AUTOANTIBODIES; AUTOANTIGENS; AUTOIMMUNITY; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RADIOTHERAPY; RED-CELL APLASIA, PURE; SPLENECTOMY;

EID: 0035382941     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-001-0039-z     Document Type: Article

References (26)

1. Rozman C, Montserrat E: Chronic lymphocytic leukemia. N Engl J Med 1995, 333:1052–1057. DOI: 10.1056/NEJM199510193331606
2. O’Brien S, del Gigilio A, Keating M: Advances in the biology and treatment of B-cell chronic lymphocytic leukemia. Blood 1995, 85:307–318.
3. Rai KR, Sawitsky A, Cronkite EP, et al.: A new prognostic classification of chronic lymphocytic leukemia. Blood 1975, 46:219–234.
4. Binet JL, Auguier A, Dighiero G, et al.: A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981, 48:198–216. DOI: 10.1002/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V
5. Bartik MM, Welker D, Kay NE: Impairments in immune cell function in B-cell chronic lymphocytic leukemia. Semin Oncol 1998, 25:27–33.
6. Mauro FR, Foa R, Cerretti R, et al.: Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. Blood 2000, 95:2786–2792. This study reviews AIHA in a series of 1203 patients with CLL, and details the risk factors and treatment. This series suggests that steroids may be more useful in CLL-associated AIHA than in AIHA without an associated lymphoproliferative disorder.
7. Diehl LF, Ketchum LH: Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia. Semin Oncol 1998, 25:80–97. This recent review article details autoimmune disease associated with CLL as well as other hematopoietic malignancies. A comprehensive list of interventions and their results is provided, with 151 references.
8. Zipps T, Carson DA: Autoantibodies in chronic lymphocytic leukemia and related systemic autoimmune diseases. Blood 1993, 81:2475–2487.
9. Rai KR, Peterson BL, Frederick R, et al.: Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000, 343:1750–1757. This randomized, prospective trial of 509 patients represents the most recent and best data about treatment of CLL, suggesting better response rates and longer remissions with fludarabine, but no change in overall survival. DOI: 10.1056/NEJM200012143432402
10. Pritsch O, Maloum K, Dighiero G: Basic biology of autoimmune phenomena in chronic lymphocytic leukemia. Semin Oncol 1998, 25:34–41.
11. George JN, El-Harake MA, Raskob GE: Chronic idiopathic thrombocytopenic purpura. N Engl J Med 1994, 331:1207–1211. This concise review summarizes the state of the art in management of chronic ITP. DOI: 10.1056/NEJM199411033311807
12. Julisson G: Complications in the treatment of CLL with purine analogues. Hematol Cell Ther 1997, 39({supp}):S41-S44. DOI: 10.1007/s00282-997-0041-4
13. Bastion Y, Coiffer B, Dumontet C, et al.: Severe autoimmune hemolytic anemia in two patients treated with fludarabine for CLL. Ann Oncol 1992, 3:171–172.
14. Tosti S, Caruso R, D’Adamo F, et al.: Severe autoimmune hemolytic anemia in a patient with CLL responsive to fludarabine-based treatment. Ann Hematol 1992, 65:238–239. DOI: 10.1007/BF01703953
15. Chasty RC, Myint H, Oscier DG, et al.: Autoimmune haemolysis in patients with B-CLL treated with chlorodeoxyadenosine. Leuk Lymphoma 1998, 29:391–398.
16. Myint H, Copplestone JA, Orchard J, et al.: Fludarabine related autoimmune haemolytic anemia in patients with chronic lymphocytic leukemia. Br J Haematol 1995, 91:341–344.
17. Schlegel PJ, Samlowski WE, Ward JH: Autoimmune hemolytic anemia in a patient with chronic lymphocytic leukemia and renal cell carcinoma after treatment with high-dose intravenous bolus Interleukin-2. J Immunother 2000, 23:507–508. DOI: 10.1097/00002371-200007000-00016
18. Berchtold P, McMillan R: Therapy of chronic idiopathic thrombocytopenia purpura. Blood 1989, 74:2309–2317.
19. Weeks JC, Tierney MR, Weinstein MC: Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Engl J Med 1991, 325:81–86. DOI: 10.1056/NEJM199107113250202
20. Anderson JC: Response of resistant idiopathic thrombocytopenic purpura to pulsed high-dose dexamethasone therapy. N Engl J Med 1994, 330:1560–1564. DOI: 10.1056/NEJM199406023302203
21. Reiner A, Gensheimer, Slichter SJ: Pulse cyclophosphamide therapy for refractory autoimmune thrombocytopenic purpura. Blood 1995, 85:351–358.
22. Figueroa M, Gehlsen J, Hammond D, et al.: Combination chemotherapy in refractory immune thrombocytopenia. N Engl J Med 1993, 328:1226–1229. DOI: 10.1056/NEJM199304293281703
23. Facon T, Caulier MT, Fenaux P, et al.: Accessory spleen in recurrent chronic immune thrombocytopenic purpura. Am J Hematol 1992, 41:184–189. DOI: 10.1002/ajh.2830410308
24. Calverley DC, Jones GW, Kelton JG: Splenic radiation for corticosteroid-resistant immune thrombocytopenia. Ann Intern Med 1992, 116:977–981.
25. Juliusson G, Elmhom-Rosenborg A, Liliemark J:Response to 2-chlorodeoxyadenosine in patient with B-cell chronic lymphocytic leukemia resistant to fludarabine. N Engl J Med 1992, 327:1056–1061. DOI: 10.1056/NEJM199210083271504
26. Saven A, Lemon RH, Kosty M, et al.: 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J Clin Oncol 1995, 13:570–574.